Skip to main content
SpringerLink
Log in

Chronische Herzinsuffizienz

Neue interventionelle Therapiemaßnahmen

  • Fortbildung
  • Schwerpunkt Kardiologie
  • Published:
CardioVasc Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

© K. Piayda

Abb. 2

© K. Piayda

Abb. 3

© K. Piayda

Abb. 4

© K. Piayda

Abb. 5

© K. Piayda

Literatur

  1. Bozkurt B, Coats AJS, Tsutsui H et al. Universal definition and classification of heart failure: A report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by Canadian Heart Failure Society, Heart Failure Association of India, the Cardiac Society of Australia and New Zealand, and the Chinese Heart Failure Association. Eur J Heart Fail. 2021;23(3):352-80

  2. Virani SS, Alonso A, Aparicio HJ et al. Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association. Circulation. 2021;143(8):e254-e743

  3. Heidenreich PA, Trogdon JG, Khavjou OA et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011;123(8):933-44

  4. Crespo-Leiro MG, Metra M, Lund LH et al. Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2018;20(11):1505-35

  5. Baskett RJ, Exner DV, Hirsch GM, Ghali WA. Mitral insufficiency and morbidity and mortality in left ventricular dysfunction. Can J Cardiol. 2007;23(10):797-800

  6. Khan MS, Siddiqi TJ, Butler J et al. Functional outcomes with Carillon device over 1 year in patients with functional mitral regurgitation of Grades 2+ to 4+: results from the REDUCE-FMR trial. ESC Heart Fail. 2021;8(2):872-8

  7. Vargas Abello LM, Klein AL, Marwick TH et al. Understanding right ventricular dysfunction and functional tricuspid regurgitation accompanying mitral valve disease. J Thorac Cardiovasc Surg. 2013;145(5):1234-41 e5

  8. Lurz P, von Bardeleben SR, Weber M et al. Transcatheter Edge-to-Edge Repair for Treatment of Tricuspid Regurgitation. J Am Coll Cardiol. 2021;77(3):229-39

  9. Verbrugge FH, Dupont M, Bertrand PB et al. Pulmonary vascular response to exercise in symptomatic heart failure with reduced ejection fraction and pulmonary hypertension. Eur J Heart Fail. 2015;17(3):320-8

  10. Rodes-Cabau J, Bernier M, Amat-Santos IJ et al. Interatrial Shunting for Heart Failure: Early and Late Results From the First-in-Human Experience With the V-Wave System. JACC Cardiovasc Interv. 2018;11(22):2300-10

  11. Guimaraes L, Bergeron S, Bernier M et al. Interatrial shunt with the second-generation V-Wave system for patients with advanced chronic heart failure. EuroIntervention. 2020;15(16):1426-8

  12. Feldman T, Mauri L, Kahwash R et al. Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction (REDUCE LAP-HF I [Reduce Elevated Left Atrial Pressure in Patients With Heart Failure]): A Phase 2, Randomized, Sham-Controlled Trial. Circulation. 2018;137(4):364-75

  13. Shah SJ, Feldman T, Ricciardi MJ et al. One-Year Safety and Clinical Outcomes of a Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction in the Reduce Elevated Left Atrial Pressure in Patients With Heart Failure (REDUCE LAP-HF I) Trial: A Randomized Clinical Trial. JAMA Cardiol. 2018;3(10):968-77

  14. Paitazoglou C, Bergmann MW, Ozdemir R et al. One-year results of the first-in-man study investigating the Atrial Flow Regulator for left atrial shunting in symptomatic heart failure patients: the PRELIEVE study. Eur J Heart Fail. 2021;23(5):800-10

  15. Gooley RP, Meredith IT. The Accucinch transcatheter direct mitral valve annuloplasty system. EuroIntervention. 2015;11 Suppl W:W60-1

  16. Loforte A, Alfonsi J, Gliozzi G et al. Less invasive ventricular enhancement (LIVE) as potential therapy for ischaemic cardiomyopathy end-stage heart failure. J Thorac Dis. 2019;11(Suppl 6):S921-S8

  17. Abraham WT, Zile MR, Weaver FA et al. Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection Fraction. JACC Heart Fail. 2015;3(6):487-96

  18. Bisognano J, Schneider JE, Davies S et al. Cost-impact analysis of baroreflex activation therapy in chronic heart failure patients in the United States. BMC Cardiovasc Disord. 2021;21(1):155

  19. Spiering W, Williams B, Van der Heyden J et al. Endovascular baroreflex amplification for resistant hypertension: a safety and proof-of-principle clinical study. Lancet. 2017;390(10113):2655-61

Download references

Author information

Authors and Affiliations

  1. CardioVasculäres Centrum Frankfurt, Seckbacher Landstrasse 65, 60389, Frankfurt am Main, Germany

    Kerstin Piayda

  2. St. Katharinen-Krankenhaus, CardioVasculäres Centrum Frankfurt CVC, Seckbacher Landstr. 65, 60389, Frankfurt\/M., Germany

    Horst Sievert

Authors
  1. Kerstin Piayda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Horst Sievert
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kerstin Piayda.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Piayda, K., Sievert, H. Neue interventionelle Therapiemaßnahmen. CV 21, 47–53 (2021). https://doi.org/10.1007/s15027-021-3543-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15027-021-3543-z

Search

Navigation